PRECISION BIOSCIENCES INC — Director's Dealing 2019

Mar 27, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27

Reporting Person: venBio Global Strategic Fund, L.P. (Director, 10% Owner)
Reporting Person: venBio Global Strategic GP, L.P. (10% Owner)
Reporting Person: venBio Global Strategic GP, Ltd. (10% Owner)
Reporting Person: Adelman Robert J (Director, 10% Owner)
Reporting Person: GOODMAN COREY S (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (3747623)		Indirect
Series B Preferred Stock	$		Common Stock (467518)		Indirect

Footnotes

F1: Each share of the Issuer's preferred stock is convertible, at any time, at the holder's election, into shares of the Issuer's common stock, $0.000005 par value per share (the "Common Stock"). Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock and Series B Preferred Stock will convert into shares of Common Stock on a one-for-2.134686 basis, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering. Neither the Series A Preferred Stock nor the Series B Preferred Stock has an expiration date.

F2: venBio Global Strategic GP, L.P. is the sole general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.